Ozempic, Wegovy, Mounjaro Lawsuits: Drugmakers Accused of Hiding Health Risks

Case Overview: Over 1,300 lawsuits allege that the makers of Ozempic, Wegovy, and Mounjaro hid serious health risks, including gastroparesis, from patients.

Consumers Affected: Patients who experienced serious side effects after using Ozempic, Wegovy, or Mounjaro.

Court: Multidistrict litigation (MDL) in Pennsylvania

Novo Nordisk and Eli Lilly, manufacturers of popular diabetes and weight loss drugs like Ozempic, Wegovy, and Mounjaro, are facing over 1,300 lawsuits alleging they failed to warn users about dangerous side effects. 

The lawsuits, now part of multidistrict litigation (MDL) in Pennsylvania, focus on severe health problems linked to these medications, including gastroparesis, which slows stomach emptying.

Patients involved in the lawsuits claim the companies promoted the drugs as effective weight loss solutions while downplaying the risks of debilitating side effects. These medications belong to a class of drugs called GLP-1 receptor agonists, which are often prescribed to help manage blood sugar levels in type 2 diabetes and support weight management.

CLICK HERE FOR A FREE CLAIM REVIEW FROM AN OZEMPIC LAWYER

Patients Allege Serious Side Effects from Ozempic, Wegovy, Mounjaro, and Zepbound

The lawsuits allege that patients experienced a range of severe side effects after using the drugs, including persistent nausea, vomiting, diarrhea, bowel obstructions, pancreatitis, and other gastrointestinal issues. Gastroparesis has been a major focus of the litigation, with claims that the condition has caused lasting harm for some users.

According to the complaints, Novo Nordisk and Eli Lilly were aware of these potential risks but failed to provide adequate warnings in their product labeling and marketing materials. The companies are accused of emphasizing the benefits of weight loss while leaving out critical information about the possible health complications.

Patients also argue that the advertised weight loss benefits were overstated. While some saw results, others reported little improvement or were forced to stop using the medications due to side effects.

Lawsuits Seek Compensation and Changes to Drug Labeling

The MDL, formed earlier this year, has rapidly expanded as more patients file lawsuits. Plaintiffs are seeking compensation for medical expenses, lost income, and damages related to their use of the drugs. They are also calling for changes to labeling and marketing practices to ensure future users are fully informed about the risks.

Federal regulators have recently added warnings to GLP-1 drug labels, cautioning about slowed stomach emptying and complications during surgeries requiring anesthesia. These updates reflect growing concerns over the safety of these medications.

The lawsuits aim to determine whether Novo Nordisk and Eli Lilly misled patients and healthcare providers about the risks associated with their products, and whether the companies should be held accountable for the alleged harm caused by their medications.

SEE IF YOU QUALIFY TO FILE AN OZEMPIC LAWSUIT, FILL OUT THE FORM HERE

Case Details

• Lawsuit: In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation
• Case Number: MDL No. 3094, 2:24-md-3094-KSM
• Court: U.S. District Court for the Eastern District of Pennsylvania

Plaintiffs' Attorneys

• Paul J. Pennock (Morgan & Morgan, P.A.)
• Parvin K. Aminolroaya (Seeger Weiss LLP)
• Jonathan Orent (Motley Rice LLC)
• Sarah Ruane (Wagstaff & Cartmell)

Have you experienced side effects from Ozempic, Wegovy, or Mounjaro? Share your experience in the comments below.